Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: macitentan Clear all

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Macitentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 20 more

Conditions: Congenital Heart Disease
Interventions: Macitentan 10 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 3 more

Conditions: Systemic Sclerosis, Ulcers
Interventions: macitentan 3mg, macitentan 10mg, placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Aventura, Florida + 12 more

Conditions: Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
Interventions: Opsumit 10 Mg Tablet; Drug
Lead sponsor: Franz Rischard, DO; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Pulmonary Arterial Hypertension
Interventions: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan 10 mg tablet, once daily.; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Las Vegas, Nevada + 2 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Macitentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more

Conditions: Pulmonary Hypertension
Interventions: Macitentan 10mg, Placebo sugar pill; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 50
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan, Tadalafil, Selexipag; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Glioblastoma
Interventions: Phase 1 Dose Escalation, Phase 1b, Ancillary Study; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Notapplicable; Other
Lead sponsor: Actelion; Industry
Eligibility: Not listed
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 105
States / cities: Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more

Conditions: Hypertension, Pulmonary
Interventions: Tadalafil, Placebo, ERA as specific PAH treatment; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 7
States / cities: Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more

Conditions: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions: FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 26
States / cities: Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more

Conditions: Healthy
Interventions: FDC of Macitentan and Tadalafil, Macitentan, Tadalafil; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants